Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma (DESPARTH)
Phase I Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Oral Artesunate (ART) in Patients With Advanced Hepatocellular Carcinoma (HCC).
Sponsor: Anticancer Fund, Belgium
Terminated
slow recruitment of patients
Other terminated trials from Anticancer Fund, Belgium
Other Hepatocellular Carcinoma trials with similar outcome
A PHASE1 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Anticancer Fund, Belgium and has accumulated 6 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anticancer Fund, Belgium
- University Ghent
- University Hospital, Ghent
For direct contact, visit the study record on ClinicalTrials.gov .